Personalized treatment aided by automated analysis of fluid in active neovascular age-related macular degeneration (nAMD) in a prospective, multicenter, randomized study
Latest Information Update: 11 Sep 2023
At a glance
- Drugs Aflibercept (Primary) ; Bevacizumab (Primary) ; Brolucizumab (Primary) ; Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
Most Recent Events
- 01 May 2023 Trial design published in the Eye.
- 02 Oct 2020 Planned number of patients changed from 50 to 290.
- 26 Feb 2020 New trial record